Skip to content

Efficacy and safety of standard therapy combined with all-site radiotherapy for GG5 metastatic prostate cancer

Efficacy and safety of standard therapy combined with all-site radiotherapy for GG5 metastatic prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119199
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Intensive Treatment Group:None

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Initial puncture pathology or postoperative pathology confirms GS 9-10 points. 2.Patients with radiological confirmation of distant metastases. 3.Treatment regimen: all-site radiotherapy + standard systemic therapy (ADT + novel hormonal therapy ± chemotherapy). The radiotherapy protocol includes: all-site radiotherapy targeting all metastatic lesions or all residual active disease following systemic therapy. 4.Expected survival exceeding 12 months. 5.Age >= 18 years. 6.KPS>=80 points. 7.White blood cell count >= 3.5 × 10^9/L, neutrophil count >= 1.5 × 10^9/L, platelet count >= 100.0 × 10^9/L, haemoglobin >= 90 g/L. 8.Informed consent of the subject.

Exclusion criteria

Exclusion criteria: 1.Previous history of malignant tumors (except for tumors that have been cured for more than 5 years). 2.Previous abdominal radiotherapy. 3.Weight loss exceeding 10% within the past six months. 4.Individuals with pre-existing or concomitant bleeding disorders. 5.Active infection. 6.Clinically evident cardiac disease (e.g., drug-resistant hypertension, unstable angina pectoris, congestive heart failure at New York Heart Association [NYHA] class >= II, unstable symptomatic arrhythmia, or peripheral vascular disease at >= NYHA class II). 7.Individuals are unable to provide informed consent due to psychological, familial, or social factors.

Design outcomes

Primary

MeasureTime frame
Castration-Resistant Prostate Cancer-Free Survival;Progression-free survival;

Secondary

MeasureTime frame
Overall Survival;PSA progression-free survival;Prostate Cancer-Specific Survival;

Countries

China

Contacts

Public ContactXianshu Gao

Peking University First Hospital

gao7777@139.com+86 10 83575239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026